Analysis J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
6/2/2024
Analysis of J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
J. B. Chemicals & Pharmaceuticals Limited has been showing some fluctuations in its stock price recently. The RSI indicator has been hovering around the 50 mark, indicating a neutral sentiment in the market. The MACD indicator has been negative, suggesting a bearish trend in the short term.The stock price has been moving around the moving averages, with the EMA showing a slight downward trend. The WMA has also been fluctuating, indicating some volatility in the stock price.
Overall, the stock seems to be experiencing some uncertainty in the market, with mixed signals from the technical indicators. Traders and investors may want to closely monitor the stock price movement and wait for a clearer trend to emerge before making any trading decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a range from $1.18 to $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter last year.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is higher at $1.42, with a range from $1.33 to $1.51. This is also an increase from the EPS of $1.35 in the same quarter a year ago.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS is projected to be $6.10, ranging from $5.95 to $6.41. This indicates growth from the EPS of $5.67 in the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a range from $5.92 to $7.31. This forecast suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates remains at 25.
3. Looking at the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates has increased to 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with a more substantial increase expected in the next fiscal year. The growing number of analysts providing estimates indicates continued interest and attention from the investment community in the company's performance.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is expected to experience steady growth in the short term and moderate growth in the long term according to analyst consensus.
Price target
The analysts' forecast for the future price of the security paper is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security paper, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating that there is potential for growth according to the analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, the quarter ending on August 1, 2024, had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and healthy return on assets and equity. The balance sheet shows a decent current ratio, but a relatively high total debt to equity ratio. The income statement indicates significant revenue and EBITDA, with a good gross profit margin and diluted EPS.
Moving on to stock statistics, the company has a low short ratio and short percent of shares outstanding, with a significant percentage held by institutions. The stock price summary shows a beta above 1, with the stock trading within a range of fifty-two-week low and high prices.
Valuation metrics reveal a high PEG ratio and price to book ratio, with the stock trading at a relatively high forward and trailing PE. The enterprise value, market capitalization, and other ratios provide insights into the company's valuation.
Lastly, dividends and splits information includes details on dividend dates, payout ratios, and dividend yields, along with historical split factors. This data gives investors a comprehensive overview of the company's financial health and market performance.
Income statement 💸
These are revenue figures. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing over the years, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased from $3.28 in 2020 to $6.16 in 2023.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA reaching $129.2 billion in 2023.
7. Despite an increase in income tax expenses, the company has managed to grow its net income continuously.
8. The company has been able to control its operating expenses effectively, allowing for growth in operating income.
9. Non-operating interest expenses have been relatively stable over the years.
10. The number of basic and diluted shares outstanding has remained stable, indicating no significant dilution of shares.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown fluctuations but has generally been on an upward trend.
6. The company has been managing its short-term and long-term debts while investing in non-current assets for future growth.
7. Accumulated depreciation has been significant, affecting the value of non-current assets.
8. The company has been retaining earnings and issuing common stock to strengthen shareholders' equity.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, with large amounts being spent on common stock repurchase and debt issuance/payment.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been fluctuating, but overall, the company has maintained a healthy cash reserve.
6. Interest paid and income tax paid figures show variations, impacting the company's cash flow position.
7. Stock-based compensation has been a significant factor in the company's financial activities.
8. The company has been paying dividends consistently, affecting its financing cash flow.
9. The company's net income has generally been increasing, reflecting positive financial performance over the years.
10. The company's cash flow statement reflects a mix of strategic investments, operational efficiency, and financial management decisions.
MACD of JBCHEPHARM
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
